FierceBiotechOriginal article
{"a":[{"_":"Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win ","$":{"href":"/biotech/altimmunes-next-gen-glp-1-curbs-heavy-drinking-unequivocal-ph-2-alcohol-use-disorder-win","hreflang":"en"}}]}
Phase 2positivePositive
AI Analysis
Summary
Altimmune's next-generation GLP-1/glucagon receptor dual-targeting drug demonstrated efficacy in reducing heavy drinking in a phase 2 trial for alcohol use disorder, suggesting potential therapeutic applications beyond weight loss.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Experimental GLP-1/glucagon receptor dual-targeting drug curbed heavy drinking in phase 2 trial
Importance:7/10
Sentiment:
0.80
GLP-1Glucagon receptorAlcohol use disorderPhase 2Clinical trialDrug development
Related Companies
Read the original article
Published by FierceBiotech on July 28, 2026 10:31 AM